Compounded and personalised medicine delivery covers doses mixed, diluted or assembled for one specific patient rather than a mass-manufactured batch: a chemotherapy infusion prepared to a patient's exact weight and dose, a compounded sterile preparation mixed by a hospital pharmacy, a cell or gene therapy manufactured from a patient's own cells. What every one of those has in common is that there is no second batch sitting in a warehouse if the first one is lost or damaged in transit. The dose that gets delivered is the only dose that exists.
It sits in the knowledge base next to the packaging and monitoring topics that hold a shipment's temperature intact, which matters more here than almost anywhere else in the cold chain because a failed delivery cannot simply be replaced from stock.
Short-dated by design, not by accident
A compounded sterile preparation is often mixed close to the time it will be used precisely because compounding itself introduces contamination and stability risks that a sealed, manufactured product does not carry, and the resulting expiry can be measured in hours or a few days rather than the months or years a commercially manufactured drug gets. That short dating leaves almost no slack for a delivery delay: a shipment that would arrive comfortably early against a two-year shelf life can arrive too late against a short one, so scheduling the delivery accurately matters as much as protecting the temperature. Pharmacies assign that expiry, often called a beyond-use date, from the preparation's own stability testing or a conservative default when specific data does not exist, and it is set independently for every compounded batch rather than copied from a manufactured product's label.
One dose, one patient, no substitute
A patient-specific dose, whether a compounded infusion bag labeled with one patient's name or a personalised cell therapy manufactured from that patient's own starting material, cannot be redirected to a different patient if something goes wrong, the way a batch of identical vaccine doses could be. That removes the usual safety margin cold chain logistics leans on elsewhere, extra stock, an alternate unit pulled from the same batch, and puts the full weight of the delivery on getting that one shipment right the first time. Temperature data loggers travel with these shipments more consistently than with mass-manufactured drugs for exactly this reason: there is no twin unit to check a suspect delivery against, so the logger's record often is the only evidence of what the dose actually experienced.
From the pharmacy that mixed it to the ward that gives it
Hospital compounding mostly happens in a pharmacy's own cleanroom, and the delivery leg to the ward is short, often a matter of a few floors or a short corridor walk, which keeps the temperature risk low even for a short-dated product. The harder version of the same problem shows up when the compounding pharmacy and the point of care are not in the same building: a regional compounding center supplying several hospitals, or a specialty pharmacy shipping a patient-specific dose to a clinic across a city or a state. That longer leg needs the same insulated shipper discipline as any other biologic shipment, sized down to a single dose rather than a bulk pallet.
Home infusion moves the ward into the patient's living room
Home infusion therapy extends personalised delivery one step further, past the hospital ward and into a patient's home, often for a chronic condition needing regular infusions that no longer require an inpatient stay. That setting carries the same short-dated, single-patient constraints as hospital delivery, plus the patient-handling gap seen elsewhere in home-delivered cold chain products: no professional storage, no trained handler checking the delivery on arrival, and a delivery window that has to be tight enough that the dose is used at or near the time it arrives rather than stored at home for any length of time. A visiting home health nurse administers many of these infusions, but a growing share are self-administered or given by a family caregiver with far less clinical training, which pushes the same plain-instructions problem seen elsewhere in patient-handled cold chain products onto an already time-pressured delivery.
The delivery window matters as much as the temperature band
For most cold chain products, holding the right temperature band for a generous margin of time is the whole job. For a short-dated, patient-specific preparation, the clock matters as much as the thermometer: a delivery that holds a perfect 2-8°C band but arrives after the dose has already expired is just as much a failure as one that arrives on time but warmed. That is why compounded and personalised medicine logistics is scheduled around a tight, often same-day delivery window first, with temperature control built to hold inside that window rather than a longer one.